Overview

Dapagliflozin Delays the Loss of Renal Function in Peritoneal Dialysis Patients

Status:
RECRUITING
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
This study aims to explore the role of dagliflozin in preserving the residual renal function(RRF) in peritoneal dialysis (PD) patients.
Phase:
NA
Details
Lead Sponsor:
Sichuan Academy of Medical Sciences
Treatments:
dapagliflozin